Good Manufacturing Practice (GMP) Services For Cell And Gene Therapy Global Market Report 2026

Description

Good manufacturing practice (GMP) services for cell and gene therapy involve regulated manufacturing and quality-control procedures that ensure cell- and gene-based therapies are produced safely, consistently, and in accordance with global regulatory standards. These services encompass GMP-compliant facilities, cell and viral vector processing, testing, documentation, and regulatory support for clinical and commercial applications.

The primary service types of good manufacturing practice (GMP) services for cell and gene therapy include process development, manufacturing, analytical and quality control, fill-finish, and other service types. Process development involves the design, optimization, and scale-up of cell and gene therapy production processes to ensure consistency, safety, and compliance with regulatory standards. These services are applied across therapy types including cell therapy, gene therapy, and combination therapy, and phases including preclinical, clinical, and commercial. End users include pharmaceutical and biotechnology companies, academic and research institutes, and other users.

Tariffs are impacting the GMP services for cell and gene therapy market by increasing costs of imported bioprocessing equipment, single-use consumables, analytical instruments, cold chain systems, and cleanroom infrastructure components. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on specialized imported equipment, while Asia-Pacific faces higher costs for facility expansion and technology transfer. These tariffs are increasing manufacturing service pricing and extending capacity build timelines. However, they are also driving domestic biomanufacturing investments, regional supplier development, and the establishment of localized GMP-compliant production hubs for advanced therapies.

The good manufacturing practice (gmp) services for cell and gene therapy market research report is one of a series of new reports from The Business Research Company that provides good manufacturing practice (gmp) services for cell and gene therapy market statistics, including good manufacturing practice (gmp) services for cell and gene therapy industry global market size, regional shares, competitors with a good manufacturing practice (gmp) services for cell and gene therapy market share, detailed good manufacturing practice (gmp) services for cell and gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the good manufacturing practice (gmp) services for cell and gene therapy industry. This good manufacturing practice (gmp) services for cell and gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The good manufacturing practice (gmp) services for cell and gene therapy market size has grown rapidly in recent years. It will grow from $2.49 billion in 2025 to $2.95 billion in 2026 at a compound annual growth rate (CAGR) of 18.6%. The growth in the historic period can be attributed to growth in clinical trials for advanced therapies, expansion of cell therapy research programs, increasing regulatory standardization, development of early-stage gmp facilities, rising investment in biopharmaceutical manufacturing.

The good manufacturing practice (gmp) services for cell and gene therapy market size is expected to see rapid growth in the next few years. It will grow to $5.88 billion in 2030 at a compound annual growth rate (CAGR) of 18.9%. The growth in the forecast period can be attributed to increasing commercialization of gene therapies, rising demand for scalable manufacturing capacity, expansion of personalized medicine pipelines, growing outsourcing to cdmos, increasing adoption of automated quality control systems. Major trends in the forecast period include increasing demand for commercial-scale cell and gene therapy manufacturing, rising adoption of viral vector production services, growing focus on gmp-compliant automation, expansion of fill-finish and cold chain services, enhanced emphasis on regulatory compliance.

The growing number of cell and gene therapy clinical trials is expected to propel the growth of the good manufacturing practice (GMP) services for cell and gene therapy market going forward. Cell and gene therapy trials are regulated studies that evaluate the safety, efficacy, and quality of advanced therapies using genetically modified or living cells to treat conditions such as cancer, rare genetic disorders, and autoimmune diseases. The expansion of these trials is driven by increased research and development in advanced therapies, rising investments from biotechnology and pharmaceutical companies, and growing demand for innovative treatments addressing unmet medical needs. As many trial sponsors lack in-house GMP manufacturing capabilities, they increasingly depend on specialized GMP service providers for compliant manufacturing, analytical testing, quality control, and quality assurance. These services are essential to ensure the safe, consistent, and timely supply of clinical-grade materials across trial phases. For instance, in January 2026, according to the Bioindustry Association (BIA), a UK-based national trade association, the UK had 193 ongoing advanced therapy clinical trials, with over half in early stages and more than 80% focused on gene therapies. Therefore, the increasing number of cell and gene therapy clinical trials is driving the growth of the good manufacturing practice (GMP) services for cell and gene therapy market.

Key companies operating in the good manufacturing practice (GMP) services for cell and gene therapy market are increasingly concentrating on expanding advanced manufacturing capabilities, including cell therapy manufacturing, to support regional clinical trials and accelerate therapy development timelines. Cell therapy manufacturing involves GMP-compliant processes for the collection, modification, expansion, and formulation of therapeutic cells to ensure product safety, quality, and clinical effectiveness. For example, in July 2025, AGC Biologics, a US-based contract development and manufacturing organization (CDMO), launched cell therapy process development and clinical manufacturing services at its Yokohama Technical Center in Japan. The facility supports GMP-compliant production for preclinical and clinical trials, including CAR-T therapies, induced pluripotent stem cells, and other stem cell platforms. This expansion enhances AGC Biologics' global GMP footprint across Europe, North America, and Asia, enabling faster and more compliant advancement of cell and gene therapies toward commercialization.

In May 2025, Altaris LLC, a US-based healthcare investment firm, acquired Minaris Regenerative Medicine GmbH for an undisclosed amount. Through this acquisition, Altaris, LLC aims to expand its global GMP capabilities in cell and gene therapy by integrating Minaris Regenerative Medicine's expertise in compliant manufacturing of advanced therapy products. Minaris Regenerative Medicine GmbH is a Germany-based contract development and manufacturing organization (CDMO) specializing in GMP-compliant cell and gene therapy manufacturing.

Major companies operating in the good manufacturing practice (gmp) services for cell and gene therapy market are Novartis AG, Boehringer Ingelheim BioXcellence GmbH, Batavia Biosciences B.V., FUJIFILM Diosynth Biotechnologies, AGC Biologics Inc., Lonza Group AG, WuXi AppTec Co. Ltd., BioNTech Innovative Manufacturing Services, Charles River Laboratories International Inc., Catalent Inc., Samsung Biologics Co. Ltd., Miltenyi Biotec GmbH, SK pharmteco Co. Ltd., KBI Biopharma Inc., Oxford Biomedica plc, OmniaBio Inc., RoslinCT Ltd., Pluri CDMO, SCTbio Inc., Made Scientific Inc., ENCell Co. Ltd.

North America was the largest region in the good manufacturing practice (GMP) services for cell and gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the good manufacturing practice (gmp) services for cell and gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the good manufacturing practice (gmp) services for cell and gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The good manufacturing practice (GMP) services for cell and gene therapy market includes revenues earned by entities through clinical manufacturing support, commercial scale manufacturing support, fill-finish services, cell banking services, raw material management services, quality control testing services, analytical testing services, regulatory support services, and quality assurance and compliance services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Good Manufacturing Practice (GMP) Services For Cell And Gene Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses good manufacturing practice (gmp) services for cell and gene therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for good manufacturing practice (gmp) services for cell and gene therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The good manufacturing practice (gmp) services for cell and gene therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Service Type: Process Development; Manufacturing; Analytical and Quality Control; Fill-Finish; Other Service Types
2) By Therapy Type: Cell Therapy; Gene Therapy; Combination Therapy
3) By Phase: Preclinical; Clinical; Commercial
4) By End-User: Pharmaceutical and Biotechnology Companies; Academic and Research Institutes; Other End-Users
Subsegments:
1) By Process Development: Vector Design Optimization; Cell Line Development; Upstream Process Optimization; Downstream Purification Development; Process Scale Up Studies
2) By Manufacturing: Clinical Trial Material Production; Commercial Scale Manufacturing; Viral Vector Manufacturing; Plasmid Production Services; Cell Therapy Manufacturing
3) By Analytical and Quality Control: Method Development And Validation; Potency And Efficacy Testing; Safety And Sterility Testing; Stability And Shelf Life Studies; Release Testing Services
4) By Fill-Finish: Aseptic Filling Services; Vial And Syringe Filling; Lyophilization Services; Packaging And Labeling; Cold Chain Handling
5) By Other Service Types: Regulatory Support Services; Technology Transfer Services; Supply Chain Management; Storage And Distribution; Post Manufacturing Support
Companies Mentioned: Novartis AG; Boehringer Ingelheim BioXcellence GmbH; Batavia Biosciences B.V.; FUJIFILM Diosynth Biotechnologies; AGC Biologics Inc.; Lonza Group AG; WuXi AppTec Co. Ltd.; BioNTech Innovative Manufacturing Services; Charles River Laboratories International Inc.; Catalent Inc.; Samsung Biologics Co. Ltd.; Miltenyi Biotec GmbH; SK pharmteco Co. Ltd.; KBI Biopharma Inc.; Oxford Biomedica plc; OmniaBio Inc.; RoslinCT Ltd.; Pluri CDMO; SCTbio Inc.; Made Scientific Inc.; ENCell Co. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH4MGMPG01_G26Q1

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Industry 4.0 & Intelligent Manufacturing
- 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.4 Sustainability, Climate Tech & Circular Economy
- 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
- 4.2.1 Increasing Demand For Commercial-Scale Cell And Gene Therapy Manufacturing
- 4.2.2 Rising Adoption Of Viral Vector Production Services
- 4.2.3 Growing Focus On Gmp-Compliant Automation
- 4.2.4 Expansion Of Fill-Finish And Cold Chain Services
- 4.2.5 Enhanced Emphasis On Regulatory Compliance

5. Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Analysis Of End Use Industries

5.1 Pharmaceutical Companies
5.2 Biotechnology Companies
5.3 Cell Therapy Developers
5.4 Gene Therapy Developers
5.5 Contract Development And Manufacturing Organizations (Cdmos)

6. Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Size, Comparisons And Growth Rate Analysis
7.3. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Segmentation

9.1. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Process Development, Manufacturing, Analytical and Quality Control, Fill-Finish, Other Service Types
9.2. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Cell Therapy, Gene Therapy, Combination Therapy
9.3. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Preclinical, Clinical, Commercial
9.4. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Other End-Users
9.5. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Sub-Segmentation Of Process Development, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Vector Design Optimization, Cell Line Development, Upstream Process Optimization, Downstream Purification Development, Process Scale Up Studies
9.6. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Sub-Segmentation Of Manufacturing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Clinical Trial Material Production, Commercial Scale Manufacturing, Viral Vector Manufacturing, Plasmid Production Services, Cell Therapy Manufacturing
9.7. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Sub-Segmentation Of Analytical and Quality Control, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Method Development And Validation, Potency And Efficacy Testing, Safety And Sterility Testing, Stability And Shelf Life Studies, Release Testing Services
9.8. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Sub-Segmentation Of Fill-Finish, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Aseptic Filling Services, Vial And Syringe Filling, Lyophilization Services, Packaging And Labeling, Cold Chain Handling
9.9. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Sub-Segmentation Of Other Service Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Regulatory Support Services, Technology Transfer Services, Supply Chain Management, Storage And Distribution, Post Manufacturing Support

10. Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Regional And Country Analysis

10.1. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

11.1. Asia-Pacific Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

12.1. China Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

13.1. India Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

14.1. Japan Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

15.1. Australia Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

16.1. Indonesia Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

17.1. South Korea Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

18.1. Taiwan Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

19.1. South East Asia Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

20.1. Western Europe Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

21.1. UK Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

22.1. Germany Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

23.1. France Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

24.1. Italy Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

25.1. Spain Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

26.1. Eastern Europe Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

27.1. Russia Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

28.1. North America Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

29.1. USA Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

30.1. Canada Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

31.1. South America Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

32.1. Brazil Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

33.1. Middle East Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

34.1. Africa Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market, Segmentation By Service Type, Segmentation By Therapy Type, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Regulatory and Investment Landscape

36. Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Competitive Landscape And Company Profiles

36.1. Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Company Profiles
- 36.3.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Boehringer Ingelheim BioXcellence GmbH Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Batavia Biosciences B.V. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. FUJIFILM Diosynth Biotechnologies Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. AGC Biologics Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Other Major And Innovative Companies

Lonza Group AG, WuXi AppTec Co. Ltd., BioNTech Innovative Manufacturing Services, Charles River Laboratories International Inc., Catalent Inc., Samsung Biologics Co. Ltd., Miltenyi Biotec GmbH, SK pharmteco Co. Ltd., KBI Biopharma Inc., Oxford Biomedica plc, OmniaBio Inc., RoslinCT Ltd., Pluri CDMO, SCTbio Inc., Made Scientific Inc.

38. Global Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market

41. Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market High Potential Countries, Segments and Strategies

41.1 Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market In 2030 - Countries Offering Most New Opportunities
41.2 Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market In 2030 - Segments Offering Most New Opportunities
41.3 Good Manufacturing Practice (GMP) Services for Cell and Gene Therapy Market In 2030 - Growth Strategies
- 41.3.1 Market Trend Based Strategies
- 41.3.2 Competitor Strategies

42. Appendix

42.1. Abbreviations
42.2. Currencies
42.3. Historic And Forecast Inflation Rates
42.4. Research Inquiries
42.5. The Business Research Company
42.6. Copyright And Disclaimer